Healthcare Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases

Abstract

Background The Cardio-Renal-Metabolic Syndrome (CRM) is a constellation of conditions that includes atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes (T2D). The economic consequences of developing each of these comorbidities in the context of the others has not been studied. Methods We used the electronic medical records of Kaiser Permanente Northwest (KPNW) to identify 387,985 members aged 18 or older who had a serum creatinine measured between 2005 and 2017. Patients were followed through 2019. We used a statistical approach that assesses time dependency for continuous measures; the total observation period for each patient was divided into quarters (91-day increments), and each patient contributed a record for every quarter in which they were members of the health plan. CRM status was determined for each quarter. Results The incremental annualized cost of each of these chronic diseases was similar regardless of which other conditions were present when the new condition developed. Overall costs increased by $10,316 (130%) when CKD developed, $6,789 (84%) for T2D, $21,573 (304%) for ASCVD, and $36,522 (475%) for HF. However, as a result of pre-diagnosis costs being higher as more conditions were present, the percentage increases in costs associated with incidence were lower when more prevalent conditions existed. Conclusions Onset of any new CRM condition drove substantial increase in health care costs. Our findings indicate a clear interplay of CRM conditions and emphasize the need for better simultaneous prevention and management of these disease states to reduce the economic burden on healthcare systems.